:: Volume 11, Issue 3 (5-2020) ::
Caspian J Intern Med 2020, 11(3): 310-314 Back to browse issues page
Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medication
Elnaz Faramarzi , Nayyer Jaberi , Mostafa Farahbakhsh , Alireza Ostadrahimi , Mohammad Asghari Jafarabadi , Ali Fakhari
Liver and Gastrointestinal Diseases Research center, Tabriz University of Medical sciences,Tabriz, Iran , elnazfaramarzi849@gmail.com
Abstract:   (3643 Views)
Background: This study was conducted to determine the prevalence of metabolic syndrome (Mets) in schizophrenic patients in a 6-month period of treatment with antipsychotic medications.
Methods: In this study, 60 volunteer schizophrenic patients were included. At the onset and 6 months after treatment with antipsychotic medications, fasting blood sugar (FBS), serum triglyceride (TG), high density lipoprotein (HDL), weight, waist circumference (WC), and blood pressure were determined. We defined Mets according to ATPIII criteria.
Results: After a 6-month treatment with antipsychotic drugs, the mean WC, serum TG, HDL, systolic and diastolic blood pressure increased but the changes of WC and HDL were statistically significant (p<0.05). We found that the percentage of patients with high WC, low HDL levels, and Mets increased after treatment which was statistically significant (p<0.05).
Conclusion: It is recommended that nutritional and lifestyle changes intervention should be implanted for schizophrenic patients undergoing treatment.
Keywords: schizophrenic patients, metabolic syndrome, metabolic syndrome components
Full-Text [PDF 200 kb]   (994 Downloads)    
Type of Study: Original Article | Subject: psychiatry
Received: 2019/08/27 | Accepted: 2020/02/3 | Published: 2020/05/21



XML     Print



Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 11, Issue 3 (5-2020) Back to browse issues page